<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697916</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00068525</org_study_id>
    <nct_id>NCT02697916</nct_id>
  </id_info>
  <brief_title>Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term</brief_title>
  <acronym>ADAPTABLE</acronym>
  <official_title>Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mytrus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Greater Plains Collaborative Clinical Data Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mid-South Clinical Data Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Action for Health Network (REACHnet)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patient-Centered Scalable National Network for Effectiveness Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PaTH Clinical Data Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York City Clinical Data Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health eHeart Patient Powered Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OneFlorida Clinical Data Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HealthCore-Anthem Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Humana-HUMnet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Patient-Centered Network of Learning Health Systems</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for&#xD;
      ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81&#xD;
      mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up&#xD;
      will be 50 months. The purpose of the study is to identify the optimal dose of aspirin for&#xD;
      secondary prevention in patients with Atherosclerotic cardiovascular disease (ASCVD). The&#xD;
      primary endpoint is a composite of all-cause death, hospitalization for MI, or&#xD;
      hospitalization for stroke. The primary safety endpoint is hospitalization for major bleeding&#xD;
      with an associated blood product transfusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pragmatic, patient-centered clinical trial, the investigators will compare the&#xD;
      effectiveness of two doses of aspirin (81 mg and 325 mg) currently in widespread use in the&#xD;
      United States in the secondary-prevention population of patients with established ASCVD. The&#xD;
      trial will use a novel format that uses existing electronic health records (EHRs), as well as&#xD;
      a web-based patient portal to collect patient-reported outcomes (PROs), and available patient&#xD;
      encounter data to supplement/support the EHR. Patients who are identified as candidates for&#xD;
      the trial will be directed to the electronic patient portal for the eConsent as well as an&#xD;
      abbreviated eligibility confirmation and randomization. One of the important aims of&#xD;
      ADAPTABLE is to engage patients, their healthcare providers, and trial investigators in using&#xD;
      the infrastructure PCORnet has developed and continues to refine. A total of 15,000 high-risk&#xD;
      patients with ASCVD will be randomly assigned (in an open-label fashion) in a 1:1 ratio to&#xD;
      instructions to use a daily aspirin dose of either 81 mg or 325 mg daily. The investigators&#xD;
      expect the entire sample of patients will be enrolled over 38 months, with a maximum&#xD;
      follow-up of 50 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD)</measure>
    <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All-cause Death</measure>
    <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Hospitalization for Nonfatal MI</measure>
    <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Hospitalization for Nonfatal Stroke</measure>
    <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG])</measure>
    <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Functional Status, as Measured on a 5-point Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion</measure>
    <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15076</enrollment>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>ASA 81mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin 81mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA 325mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin 325mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>81mg of aspirin daily vs. 325mg of aspirin daily</description>
    <arm_group_label>ASA 325mg</arm_group_label>
    <arm_group_label>ASA 81mg</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known atherosclerotic cardiovascular disease (ASCVD), defined by a history of prior&#xD;
             myocardial infarction, prior coronary angiography showing ≥75% stenosis of at least&#xD;
             one epicardial coronary vessel, or prior coronary revascularization procedures (either&#xD;
             PCI or CABG), or history of chronic heart disease, CAD, ASCVD&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  No known safety concerns or side effects considered to be related to aspirin,&#xD;
             including&#xD;
&#xD;
          -  No history of significant allergy to aspirin such as anaphylaxis, urticaria, or&#xD;
             significant gastrointestinal intolerances&#xD;
&#xD;
          -  No history of significant GI bleed within the past 12 months&#xD;
&#xD;
          -  Significant bleeding disorders that preclude the use of aspirin&#xD;
&#xD;
          -  Access to the Internet. In the event that the CDRNs are notified that a cohort of&#xD;
             patients without internet access can be included, then patient agreement will be&#xD;
             obtained during the consent process to provide follow-up information by telephone&#xD;
             contact with the DCRI Call Center.&#xD;
&#xD;
          -  Not currently treated with an oral anticoagulant - either warfarin or a novel&#xD;
             anticoagulant (dabigatran, rivaroxaban, apixaban, edoxaban) - and not planned to be&#xD;
             treated in the future with an oral anticoagulant for existing indications such as&#xD;
             atrial fibrillation, deep venous thrombosis, or pulmonary embolism.&#xD;
&#xD;
          -  Not currently treated with ticagrelor and not planned to be treated in the future with&#xD;
             ticagrelor.&#xD;
&#xD;
          -  Female patients who are not pregnant or nursing an infant&#xD;
&#xD;
          -  Estimated risk of a major cardiovascular event (MACE) &gt; 8% over next 3 years as&#xD;
             defined by the presence of at least one or more of the following enrichment factors:&#xD;
&#xD;
          -  Age &gt; 65 years&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
          -  Diabetes mellitus (Type 1 or Type 2)&#xD;
&#xD;
          -  3-vessel coronary artery disease&#xD;
&#xD;
          -  Cerebrovascular disease and/or peripheral arterial disease&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 50%&#xD;
&#xD;
          -  Current cigarette smoker&#xD;
&#xD;
          -  Chronic systolic or diastolic heart failure&#xD;
&#xD;
          -  SBP &gt; 140 (within past 12 mos)&#xD;
&#xD;
          -  LDL &gt; 130 (within past 12 mos)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There will be no exclusions for any upper age limit, comorbid conditions, or&#xD;
             concomitant medications other than oral anticoagulants and ticagrelor that are used at&#xD;
             the time of randomization, or are planned to be used during the study follow-up.&#xD;
&#xD;
          -  Patients and sites interested in participating must be part of the listed health&#xD;
             systems collaborators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William S. Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian F. Hernandez, MD MHS FAHA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthCore</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Cardiology - Springhill</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bond Community Health Center</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Heart &amp; Vascular Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Health St. Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allina Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68196</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univerity</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospitals and Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://theaspirinstudy.org/</url>
    <description>ADAPTABLE public website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <results_first_submitted>June 9, 2021</results_first_submitted>
  <results_first_submitted_qc>June 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2021</results_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>ACSD</keyword>
  <keyword>PCORI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02697916/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02697916/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ASA 81mg</title>
          <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
        </group>
        <group group_id="P2">
          <title>ASA 325mg</title>
          <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7540"/>
                <participants group_id="P2" count="7536"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6962"/>
                <participants group_id="P2" count="6828"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="578"/>
                <participants group_id="P2" count="708"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="315"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="393"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ASA 81mg</title>
          <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
        </group>
        <group group_id="B2">
          <title>ASA 325mg</title>
          <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7540"/>
            <count group_id="B2" value="7536"/>
            <count group_id="B3" value="15076"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" lower_limit="60.7" upper_limit="73.6"/>
                    <measurement group_id="B2" value="66.8" lower_limit="60.37" upper_limit="73.5"/>
                    <measurement group_id="B3" value="66.8" lower_limit="60.7" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2307"/>
                    <measurement group_id="B2" value="2417"/>
                    <measurement group_id="B3" value="4724"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5233"/>
                    <measurement group_id="B2" value="5119"/>
                    <measurement group_id="B3" value="10352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="481"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6816"/>
                    <measurement group_id="B2" value="6737"/>
                    <measurement group_id="B3" value="13553"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="475"/>
                    <measurement group_id="B2" value="567"/>
                    <measurement group_id="B3" value="1042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="664"/>
                    <measurement group_id="B2" value="647"/>
                    <measurement group_id="B3" value="1311"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6014"/>
                    <measurement group_id="B2" value="5976"/>
                    <measurement group_id="B3" value="11990"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="640"/>
                    <measurement group_id="B2" value="741"/>
                    <measurement group_id="B3" value="1381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD)</title>
        <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASA 81mg</title>
            <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
          <group group_id="O2">
            <title>ASA 325mg</title>
            <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All-cause Death, Hospitalization for Nonfatal MI, or Hospitalization for Nonfatal Stroke in High-risk Patients With a History of MI or Documented Atherosclerotic Cardiovascular Disease (ASCVD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7434"/>
                <count group_id="O2" value="7330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="590"/>
                    <measurement group_id="O2" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All-cause Death</title>
        <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASA 81mg</title>
            <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
          <group group_id="O2">
            <title>ASA 325mg</title>
            <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All-cause Death</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7434"/>
                <count group_id="O2" value="7330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315"/>
                    <measurement group_id="O2" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Hospitalization for Nonfatal MI</title>
        <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASA 81mg</title>
            <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
          <group group_id="O2">
            <title>ASA 325mg</title>
            <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Hospitalization for Nonfatal MI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7434"/>
                <count group_id="O2" value="7330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Hospitalization for Nonfatal Stroke</title>
        <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASA 81mg</title>
            <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
          <group group_id="O2">
            <title>ASA 325mg</title>
            <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Hospitalization for Nonfatal Stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7434"/>
                <count group_id="O2" value="7330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG])</title>
        <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASA 81mg</title>
            <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
          <group group_id="O2">
            <title>ASA 325mg</title>
            <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Coronary Revascularization Procedures (Percutaneous Coronary Intervention [PCI] or Coronary Artery Bypass Grafting [CABG])</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7434"/>
                <count group_id="O2" value="7330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471"/>
                    <measurement group_id="O2" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life and Functional Status, as Measured on a 5-point Scale</title>
        <description>Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASA 81mg</title>
            <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
          <group group_id="O2">
            <title>ASA 325mg</title>
            <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life and Functional Status, as Measured on a 5-point Scale</title>
          <description>Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7540"/>
                <count group_id="O2" value="7536"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Describe Current Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread=".011"/>
                    <measurement group_id="O2" value="2.8" spread=".011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Able to Run Errands and Shop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread=".011"/>
                    <measurement group_id="O2" value="1.66" spread=".012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In the past 7 Days, Felt Depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread=".010"/>
                    <measurement group_id="O2" value="1.7" spread=".011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In the past 7 Days, Felt Fatigued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread=".012"/>
                    <measurement group_id="O2" value="2.27" spread=".012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In the past 7 Days, Problems with Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread=".012"/>
                    <measurement group_id="O2" value="2.10" spread=".012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trouble doing Regular Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread=".012"/>
                    <measurement group_id="O2" value="1.88" spread=".012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In the past 7 Days, Pain interfered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread=".013"/>
                    <measurement group_id="O2" value="2.02" spread=".013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion</title>
        <time_frame>Time of randomization through study completion, approximately 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASA 81mg</title>
            <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
          <group group_id="O2">
            <title>ASA 325mg</title>
            <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Hospitalization for Major Bleeding Complications With an Associated Blood Product Transfusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7434"/>
                <count group_id="O2" value="7330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 50 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ASA 81mg</title>
          <description>aspirin 81mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
        </group>
        <group group_id="E2">
          <title>ASA 325mg</title>
          <description>aspirin 325mg&#xD;
aspirin: 81mg of aspirin daily vs. 325mg of aspirin daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="7434"/>
                <counts group_id="E2" subjects_affected="357" subjects_at_risk="7330"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="383" subjects_at_risk="7434"/>
                <counts group_id="E2" subjects_affected="349" subjects_at_risk="7330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Fatal MI</sub_title>
                <counts group_id="E1" events="228" subjects_affected="228" subjects_at_risk="7434"/>
                <counts group_id="E2" events="213" subjects_affected="213" subjects_at_risk="7330"/>
              </event>
              <event>
                <sub_title>Major Bleeding</sub_title>
                <description>Major Bleeding requiring transfusion</description>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="7434"/>
                <counts group_id="E2" events="44" subjects_affected="44" subjects_at_risk="7330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Fatal Stroke</sub_title>
                <counts group_id="E1" events="102" subjects_affected="102" subjects_at_risk="7434"/>
                <counts group_id="E2" events="92" subjects_affected="92" subjects_at_risk="7330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="491" subjects_at_risk="7434"/>
                <counts group_id="E2" subjects_affected="471" subjects_at_risk="7330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PCI or CABG</sub_title>
                <counts group_id="E1" events="471" subjects_affected="471" subjects_at_risk="7434"/>
                <counts group_id="E2" events="446" subjects_affected="446" subjects_at_risk="7330"/>
              </event>
              <event>
                <sub_title>Transient ischemia attack (TIA)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="7434"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="7330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>W. Schuyler Jones, MD</name_or_title>
      <organization>Duke University; Duke Clinical Research Institute</organization>
      <phone>919-668-8917</phone>
      <email>schuyler.jones@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

